• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与中枢神经系统转移长期生存相关的因素。

Factors associated with long-term survival in central nervous system metastases.

机构信息

Neuro-oncology Unit, Instituto Nacional de Cancerología, Av. San Fernando 22 Col Sección XVI, ZC 14050, Mexico City, México.

Neuro-oncology Unit, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.

出版信息

J Neurooncol. 2018 Oct;140(1):159-164. doi: 10.1007/s11060-018-2946-x. Epub 2018 Jul 12.

DOI:10.1007/s11060-018-2946-x
PMID:30003395
Abstract

BACKGROUND

Cancer is a leading cause of death worldwide; central nervous system metastases (CNSm) are amongst the most common complications of cancer and are associated with high morbidity and mortality. The aim of the study was to associate clinic and oncologic characteristics with the possibility of survival for ≥ 1 year.

MATERIALS AND METHODS

A prospective cohort in two referral centers recollected clinical and oncologic data from patients diagnosed with CNSm. Chronic metastases were defined as those patients that survived for ≥ 12 months after the diagnosis of CNSm.

RESULTS

Of 613 patients with CNSm, 554 had solid tumors as the primary cancer and were included; 405 (73%) were women, the most common primary cancer site were breast, lung and urologic. Chronic CNSm were found in 260 (47%) and were compared to those who did not. After multivariate logistic regression analysis, variables associated with good prognosis (living > 12 months) were: female sex (HR 0.55), single CNSm (HR 0.39), diagnosis of CNSm during initial extension studies or during presentation of cancer (HR 0.43), and occipital location (HR 0.62).

CONCLUSIONS

Long-term survival in patients with CNSm remains a topic of debate; their bad prognosis could be changing towards improvement. Clinical findings are typically overlooked in CNSm reports and prognostic scales. After our findings, we propose to include them in forthcoming studies to aid prognostic considerations. Factors associated with prolonged survival found in our study include female gender, timing of CNSm diagnosis, occipital lobe location, and single CNSm.

摘要

背景

癌症是全球主要死因之一;中枢神经系统转移(CNSm)是癌症最常见的并发症之一,与高发病率和死亡率相关。本研究旨在将临床和肿瘤学特征与存活≥1 年的可能性相关联。

材料与方法

两个转诊中心的前瞻性队列回顾性地收集了诊断为 CNSm 的患者的临床和肿瘤学数据。慢性转移被定义为 CNSm 诊断后存活≥12 个月的患者。

结果

在 613 名 CNSm 患者中,554 名患有实体瘤作为原发性癌症并被纳入;405 名(73%)为女性,最常见的原发性癌症部位为乳腺、肺部和泌尿科。慢性 CNSm 见于 260 例(47%),并与未发生慢性 CNSm 的患者进行了比较。多变量逻辑回归分析后,与预后良好(存活>12 个月)相关的变量包括:女性(HR 0.55)、单发 CNSm(HR 0.39)、在初始扩展研究或癌症出现时诊断 CNSm(HR 0.43)和枕叶位置(HR 0.62)。

结论

CNSm 患者的长期生存仍然是一个有争议的话题;他们的不良预后可能正在改善。临床发现通常在 CNSm 报告和预后量表中被忽视。根据我们的发现,我们建议将其纳入即将进行的研究中,以辅助预后考虑。我们研究中发现的与延长生存相关的因素包括女性性别、CNSm 诊断时间、枕叶位置和单发 CNSm。

相似文献

1
Factors associated with long-term survival in central nervous system metastases.与中枢神经系统转移长期生存相关的因素。
J Neurooncol. 2018 Oct;140(1):159-164. doi: 10.1007/s11060-018-2946-x. Epub 2018 Jul 12.
2
Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms.识别有神经系统症状的乳腺癌患者发生中枢神经系统转移的风险因素。
Cancer. 2020 Aug 1;126(15):3456-3463. doi: 10.1002/cncr.32928. Epub 2020 May 26.
3
Prognostic factors and outcome of HER2+ breast cancer with CNS metastases.HER2+ 乳腺癌伴中枢神经系统转移的预后因素和结果。
Future Oncol. 2020 Mar;16(7):269-279. doi: 10.2217/fon-2019-0602. Epub 2020 Feb 11.
4
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.真实世界 ESME-MBC 队列中乳腺癌中枢神经系统转移患者的治疗和结局。
Eur J Cancer. 2020 Jan;125:22-30. doi: 10.1016/j.ejca.2019.11.001. Epub 2019 Dec 10.
5
Prognostic features of endometrial cancer metastasis to the central nervous system.子宫内膜癌中枢神经系统转移的预后特征。
PLoS One. 2022 Aug 26;17(8):e0268794. doi: 10.1371/journal.pone.0268794. eCollection 2022.
6
Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms.因神经系统症状导致的乳腺癌患者脑转移的诊断。
Clin Neurol Neurosurg. 2018 Oct;173:61-64. doi: 10.1016/j.clineuro.2018.08.002. Epub 2018 Aug 2.
7
Central Nervous System Metastases in Patients With Cervical Carcinoma.宫颈癌患者的中枢神经系统转移
Int J Gynecol Cancer. 2016 Nov;26(9):1686-1689. doi: 10.1097/IGC.0000000000000827.
8
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.曲妥珠单抗治疗 HER2 阳性转移性乳腺癌患者的中枢神经系统转移:来自 registHER 的患者的发生率、治疗和生存情况。
Clin Cancer Res. 2011 Jul 15;17(14):4834-43. doi: 10.1158/1078-0432.CCR-10-2962.
9
Clinical presentation, risk factors and outcome of central nervous system metastasis vs stroke in cancer patients.癌症患者中枢神经系统转移与脑卒中的临床表现、危险因素和转归。
Curr Probl Cancer. 2019 Aug;43(4):324-330. doi: 10.1016/j.currproblcancer.2018.09.001. Epub 2018 Nov 16.
10
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.

引用本文的文献

1
Efficacy of salvage stereotactic radiotherapy (SRT) for locally recurrent brain metastases after initial SRT and characteristics of target population.初始立体定向放疗(SRT)后局部复发性脑转移瘤挽救性立体定向放疗(SRT)的疗效及靶人群特征。
Clin Transl Oncol. 2021 Jul;23(7):1463-1473. doi: 10.1007/s12094-020-02544-y. Epub 2021 Jan 19.
2
Salting the Soil: Targeting the Microenvironment of Brain Metastases.盐渍土壤:靶向脑转移的微环境。
Mol Cancer Ther. 2021 Mar;20(3):455-466. doi: 10.1158/1535-7163.MCT-20-0579. Epub 2021 Jan 5.
3
Tumor microenvironment differences between primary tumor and brain metastases.

本文引用的文献

1
Molecular Sequence of Events and Signaling Pathways in Cerebral Metastases.脑转移瘤中事件的分子序列和信号通路
Anticancer Res. 2018 Apr;38(4):1859-1877. doi: 10.21873/anticanres.12424.
2
Targeted therapy of brain metastases: latest evidence and clinical implications.脑转移瘤的靶向治疗:最新证据及临床意义
Ther Adv Med Oncol. 2017 Dec;9(12):781-796. doi: 10.1177/1758834017736252. Epub 2017 Nov 15.
3
Radiobiology and radiotherapy of brain metastases.脑转移瘤的放射生物学与放射治疗
原发肿瘤与脑转移瘤之间的肿瘤微环境差异。
J Transl Med. 2020 Jan 3;18(1):1. doi: 10.1186/s12967-019-02189-8.
4
Second Re-irradiation of Brain Metastases: A Review of Studies Involving Stereotactic Radiosurgery.脑转移瘤的二次再照射:一项关于立体定向放射外科治疗研究的综述
Cureus. 2018 Dec 11;10(12):e3712. doi: 10.7759/cureus.3712.
Clin Exp Metastasis. 2017 Oct;34(6-7):411-419. doi: 10.1007/s10585-017-9865-7. Epub 2017 Nov 14.
4
Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden.非小细胞肺癌患者使用表皮生长因子受体酪氨酸激酶抑制剂后的脑转移:症状与经济负担
J Med Econ. 2017 Nov;20(11):1136-1147. doi: 10.1080/13696998.2017.1361960. Epub 2017 Aug 14.
5
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.脑转移瘤的全身治疗:非小细胞肺癌、乳腺癌和黑色素瘤。
Neuro Oncol. 2017 Jan;19(1):i1-i24. doi: 10.1093/neuonc/now197.
6
A cure is possible: a study of 10-year survivors of brain metastases.治愈是有可能的:一项针对脑转移瘤10年幸存者的研究。
J Neurooncol. 2016 Sep;129(3):545-555. doi: 10.1007/s11060-016-2208-8. Epub 2016 Jul 25.
7
Lung Cancer Brain Metastases.肺癌脑转移
Cancer J. 2015 Sep-Oct;21(5):398-403. doi: 10.1097/PPO.0000000000000146.
8
Prognostic scores for brain metastasis patients: use in clinical practice and trial design.脑转移患者的预后评分:在临床实践和试验设计中的应用。
Chin Clin Oncol. 2015 Jun;4(2):18. doi: 10.3978/j.issn.2304-3865.2015.06.01.
9
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡:GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
10
Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.乳腺癌、非小细胞肺癌、黑色素瘤和肾细胞癌脑转移的全身治疗:文献综述。
Cancer Treat Rev. 2014 Sep;40(8):951-9. doi: 10.1016/j.ctrv.2014.05.007. Epub 2014 May 27.